Ulcerative colitis and Crohn's disease are the principal forms of inflammatory bowel disease.
Both represent chronic inflammation of the gastrointestinal tract, which displays …

Although most treatment algorithms in inflammatory bowel disease (IBD) begin with
classifying patients according to disease severity, no formal validated or consensus …

Background & Aims There is limited evidence that a diet low in fermentable
oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAPs) reduces gut …

Background There has been burgeoning interest in quality of life (QoL) in inflammatory
bowel disease (IBD) in recent decades, with hundreds of studies each year now assessing …

Objective Antitumour necrosis factor (anti-TNF) drugs impair protective immunity following
pneumococcal, influenza and viral hepatitis vaccination and increase the risk of serious …

Therapeutic advances in the management of IBD have led to a paradigm shift in the
assessment of IBD disease activity. Beyond clinical remission, objective assessment of …

Abstract Background and Aims: Biosimilar infliximab CT-P13 offers the potential for large
drug acquisition cost savings. However, there are limited published data regarding its …

Abstract Background and Aims Success in delivering value-based healthcare involves
measuring outcomes that matter most to patients. Our aim was to develop a minimum …

Background Patient‐reported outcomes (PRO s) have an increasingly important role in the
evaluation of new therapies for inflammatory bowel disease. The US Food and Drug …

Abstract Background and Aims Subcutaneous [SC] vedolizumab presents the opportunity for
inflammatory bowel disease [IBD] patients to manage their treatment at home. There are …